Substantial Returns to Health-Care Spending: But Do We Spend Too Little or Too Much?
نویسندگان
چکیده
منابع مشابه
Too much or too little
The global effort to understand the molecular drivers of cancer onset and progression is now coming to fruition with the identification of specific genomic and epigenomic events that influence signaling through key oncogenic pathways. Genetic studies using inducible expression of the critical growth controlling oncogenes MYC, RAS, PI3K and AKT have shown unequivocally that, in conjunction with ...
متن کاملDo people trust too much or too little?
Across two studies, we asked whether people trust too much or too little, relative to what an economic analysis would suggest. In the trust game paradigm, participants decided whether to hand money over to an anonymous individual who could either return more money back or keep all the money. Participants trusted too little, in that they grossly underestimated the proportion of their peers who w...
متن کاملAntibiotics in intensive care: too little or too much?
T he article by Fragou et al (1), in this month’s Critical Care Medicine, provides compelling evidence that the routine use of ultrasound guidance increases the safety of central venous access by the subclavian route. In this cohort of critical care patients, cannulation was achieved in 100% of patients in the ultrasound group as compared with 87.5% in the landmark arm. Access time and the numb...
متن کاملToo much medicine; too little care.
A growing frustration in clinical medicine is that we are now so busy managing the proliferation of risk factors, “incidentalomas,” and the worried well that we lack the time to care properly for those who are seriously ill. As the definitions of common conditions such as diabetes and kidney disease have expanded and the categories and boundaries of mental disorders have grown, our time and att...
متن کاملBiologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?
We describe the development and approval of biologically targeted agents in the clinic through examples chosen from the experience with inhibitors of the epidermal growth factor (EGF) and VEGF pathways. Despite extensive biological rationale for the use of these classes of molecules, marginal clinical benefits have been observed in broad patient populations, and the agents have entered into gen...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2006
ISSN: 1098-3015
DOI: 10.1111/j.1524-4733.2006.00094.x